Business
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB)
About this update from Inmune Bio Inc.
[{"type":"text","content":"Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 PM EDT to discuss results for its first quarter ended June 30, 2024 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Fourth Quarter Conference Call when reaching the operator. Date: August 1, 2024 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-225-9448 Participant Dial-in (international): 1-203-518-9708 Conference ID: INMUNE A live audio webcast of the call can be accessed by clicking here or using this link: https://viavid.webcasts.com/starthere.jsp?ei=1679432&tp_key=8a15b560a4 A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 8, 2024 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11156467. About INmune Bio Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. XPRO, the first of several DN-TNF products, is in clinical trials to determine if it can treat patients with Mild Alzheimer’s disease. Additional therapeutic indications including d treatment-resistant depression and oncology will be pursued when resources allow. The Natural Killer Cell Priming Platform includes INKmune™, a therapy developed to prime a patient’s NK cells to treat patients with cancer. INKmune uses a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies. The INKmune trial is enrolling patients into a US Phase I/II trial in men with metasta...